ImmunityBio Posts $38.3 M Q4 Revenue, Anktiva Unit Sales Climb 750%
ImmunityBio reported revenue of $38.29 million in Q4, up from $7.56 million a year earlier, topping the $37.02 million consensus. Unit sales of lead drug Anktiva surged 750% as the company struck Middle East commercialization deals and prepared an FDA supplemental biologics license application.
1. Revenue Surge Beats Expectations
ImmunityBio delivered revenue of $38.29 million in the latest quarter, up from $7.56 million a year earlier, surpassing the consensus forecast of $37.02 million. This fivefold increase reflects the rapid adoption of its lead oncology drug and underpins recent stock gains.
2. Anktiva Sales Growth and Approvals
Unit sales of Anktiva rose 750% year-over-year as the drug secured approvals in 33 countries for non-muscle invasive bladder cancer treatment. Ongoing clinical trials in lung cancer and combination therapies signal potential expansion of its cancer treatment platform.
3. Strategic Partnerships and FDA Filing
The company established a wholly owned Saudi Arabia subsidiary and partnered with Biopharma and Cigalah Healthcare to commercialize Anktiva across the MENA region. It is also preparing to submit a supplemental biologics license application to the FDA to broaden its treatment indications.